Presenter Information

Hannah TroutFollow

Advisor(s)

Jamie Hunsicker

Confirmation

1

Document Type

Poster

Location

ONU McIntosh Center; McIntosh Activities Room

Start Date

21-4-2023 11:00 AM

End Date

21-4-2023 11:50 AM

Abstract

Abstract

Problem: Less than 25% of youth that have been diagnosed with type 1 diabetes achieve glycemic target hemoglobin A1c of less than 7.5%. Pediatric patients have difficulty with treatment plans; therefore, different medical devices are more suited to the lifestyle and activities of a pediatric diabetic patient. An intervention to increase glycemic control is continuous glucose monitoring and continuous subcutaneous insulin infusions.

Purpose: The purpose of this project is to determine the effectiveness of using a continuous blood glucose monitor compared to a self-measured blood glucose device in detecting glycemic variability and improvements in hemoglobin A1c within the pediatric population diagnosed with type 1 diabetes.

Methods: This study will be a prospective, quasi-experimental design measuring hemoglobin A1c, daily glycemic variability, and legal guardian satisfaction. Participants must be at the beginning of their treatment or have no prior use of a continuous glucose monitoring device or insulin infusion device. Hemoglobin A1c will be measured regularly with blood draws every six months, glycemic variability will be determined through the glucose measurements taken during the duration of this study, and legal guardian satisfaction will be determined through a survey at the conclusion of the study.

Conclusion: The use of continuous glucose monitors may improve glycemic control and hemoglobin A1c within the pediatric type 1 diabetic population. This is in comparison to that of a self-measured blood glucose device regardless of corrective measures such as insulin. This could be a strategy to improve pediatric diabetes management and patient outcomes

Level of Access

Restricted to ONU Community

Restricted

Available to ONU community via local IP address and ONU login.

Share

COinS
 
Apr 21st, 11:00 AM Apr 21st, 11:50 AM

Evolving Technology with Pediatric Diabetes

ONU McIntosh Center; McIntosh Activities Room

Abstract

Problem: Less than 25% of youth that have been diagnosed with type 1 diabetes achieve glycemic target hemoglobin A1c of less than 7.5%. Pediatric patients have difficulty with treatment plans; therefore, different medical devices are more suited to the lifestyle and activities of a pediatric diabetic patient. An intervention to increase glycemic control is continuous glucose monitoring and continuous subcutaneous insulin infusions.

Purpose: The purpose of this project is to determine the effectiveness of using a continuous blood glucose monitor compared to a self-measured blood glucose device in detecting glycemic variability and improvements in hemoglobin A1c within the pediatric population diagnosed with type 1 diabetes.

Methods: This study will be a prospective, quasi-experimental design measuring hemoglobin A1c, daily glycemic variability, and legal guardian satisfaction. Participants must be at the beginning of their treatment or have no prior use of a continuous glucose monitoring device or insulin infusion device. Hemoglobin A1c will be measured regularly with blood draws every six months, glycemic variability will be determined through the glucose measurements taken during the duration of this study, and legal guardian satisfaction will be determined through a survey at the conclusion of the study.

Conclusion: The use of continuous glucose monitors may improve glycemic control and hemoglobin A1c within the pediatric type 1 diabetic population. This is in comparison to that of a self-measured blood glucose device regardless of corrective measures such as insulin. This could be a strategy to improve pediatric diabetes management and patient outcomes